Patents Assigned to Pfizer Inc.
  • Publication number: 20190382359
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 19, 2019
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • Publication number: 20190382388
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 19, 2019
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Publication number: 20190382384
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: June 10, 2019
    Publication date: December 19, 2019
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Publication number: 20190382387
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 19, 2019
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Publication number: 20190382486
    Abstract: The present invention provides novel antibodies that specifically bind to CD3 and uses thereof. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: May 21, 2019
    Publication date: December 19, 2019
    Applicant: Pfizer Inc.
    Inventors: James Reasoner Apgar, Fang Jin, Madan Katragadda, Divya Mathur, Lioudmila Gennadievna Tchistiakova
  • Publication number: 20190382368
    Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Application
    Filed: July 25, 2019
    Publication date: December 19, 2019
    Applicant: PFIZER INC.
    Inventors: Eric Christian Hansen, Christopher Scott Seadeek
  • Publication number: 20190381182
    Abstract: Optimizing production of selectively capped, and uncapped, cysteines on antibodies by manipulation of cell growth conditions including the deliberate depletion of cysteine and/or cystine in the cell culture process by way of media components, batch duration, or cell density to achieve efficient production of proteins including antibody-drug-conjugates (ADCs); conjugating a TNB-capped cysteine-containing protein by reacting it with a reducing agent capable of detaching the TNB-capping moieties from the protein without significantly reducing antibody inter-chain sulfur bonds, and conjugating reduced sulfur bonds on the protein to a payload through a reactive linking moiety.
    Type: Application
    Filed: February 1, 2018
    Publication date: December 19, 2019
    Applicant: PFIZER INC.
    Inventors: Kaushik DUTTA, Jose Manuel GOMES, Frank W. KOTCH, Vimalkumar B. PATEL, Amarnauth Shastrie PRASHAD, Renee L. PROCOPIO-MELINO, Xiaotian ZHONG
  • Patent number: 10508081
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: December 17, 2019
    Assignee: Pfizer Inc.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • Patent number: 10500186
    Abstract: The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: December 10, 2019
    Assignees: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
  • Publication number: 20190365712
    Abstract: This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 5, 2019
    Applicant: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa J. Birch, Mark McAllister, Martin Rowland, Ian Leonard Smales
  • Publication number: 20190367556
    Abstract: Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 5, 2019
    Applicant: PFIZER INC.
    Inventors: Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang
  • Publication number: 20190345186
    Abstract: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 14, 2019
    Applicant: PFIZER INC.
    Inventors: Omar Khaled Ahmad, Stephen Paul Brown, Kenneth John Dirico, Russell Dushin, Gary Frederick Filzen, Sujiet Puthenveetil, Pavel Strop, Chakrapani Subramanyam, Lawrence N. Tumey
  • Patent number: 10472424
    Abstract: The present invention relates to therapeutic dosing regimens utilizing a dose reduction strategy for treating disorders characterized by marked elevations of low density protein cholesterol (LDL-C) in the plasma of a patient. The subject therapeutic dosing regimens involve delivering as a single administration or plurality of administrations of an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody as an initial dose of at least about 100 mg, and delivering as a single administration or plurality of administrations at a subsequent dose in an amount that is about the same as the initial dose, or at least half the initial dose after the patient has a LDL-C level at or below about 25, 20, 15 or 10 mg/dL, preferably at or below 10 mg/dL.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: November 12, 2019
    Assignee: Pfizer Inc.
    Inventors: Anne Barbara Cropp, Albert Kim, David Raymond Plowchalk, Kevin Richard Sweeney, Ellen Qiao Wang
  • Patent number: 10464979
    Abstract: Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 5, 2019
    Assignees: New York University, Pfizer Inc.
    Inventors: Moosa Mohammadi, Regina Goetz, Jeanne Sue Magram, Kristen Leigh Johnson
  • Patent number: 10463675
    Abstract: A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C?O, —SO2—, etc.; A? is selected from the group consisting of a bond, C?O, etc.; Z is —(CH2)h— or a bond, etc.; R1 and R1? are independently selected from the group consisting of hydrogen, alkyl, etc.; R2 is selected from hydrogen, alkyl, etc.; R3 is selected from the group consisting of hydrogen, and amino; R4 is monocyclic or bicyclic, etc.; R5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: November 5, 2019
    Assignee: Pfizer Inc.
    Inventors: Andrew Fensome, Ariamala Gopalsamy, Brian S. Gerstenberger, Ivan Viktorovich Efremov, Zhao-Kui Wan, Betsy Pierce, Jean-Baptiste Telliez, John I. Trujillo, Liying Zhang, Li Xing, Eddine Saiah
  • Publication number: 20190330196
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Application
    Filed: April 23, 2019
    Publication date: October 31, 2019
    Applicant: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Publication number: 20190331687
    Abstract: Diagnostic methods for predicting whether a human tumor is sensitive to treatment with axitinib, and methods of treating a human tumor are disclosed. The methods are based on measurement of CD68 polypeptide expression levels in a tissue sample from a tumor. CD68 expression levels can be measured using immunohistochemistry, where the percentage of CD68-positive cells and density of CD68-positive cells within the tumor can be determined.
    Type: Application
    Filed: March 1, 2019
    Publication date: October 31, 2019
    Applicant: PFIZER INC.
    Inventors: Jean-François André MARTINI, Jamal Christo TARAZI, James Andrew WILLIAMS
  • Publication number: 20190331694
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Application
    Filed: May 24, 2019
    Publication date: October 31, 2019
    Applicants: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
  • Publication number: 20190330352
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Application
    Filed: October 5, 2017
    Publication date: October 31, 2019
    Applicants: PFIZER INC, MERCK PATENT GmbH
    Inventors: Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
  • Patent number: D865198
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 29, 2019
    Assignee: Pfizer Inc.
    Inventors: Clayton Jay Bigelow, Mark Edward Fagan, Chad Kamil Hickson, Amy Michelle Martini